Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Molecular Cancer Therapeutics|July 12, 2015
Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)Elena Geretti, Shannon Curtis Leonard, Nancy Dumont, et al.
Reviews of Environmental Contamination and Toxicology|September 20, 2012
Persistence, bioaccumulation, and toxicity of halogen-free flame retardantsSusanne L Waaijers, Deguo Kong, Hester S Hendriks, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|January 18, 2019
Nanoliposome targeting in breast cancer is influenced by the tumor microenvironmentNancy Dumont, Samantha Merrigan, Jason Turpin, et al.
British Journal of Cancer|October 27, 2018
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation studyPamela Munster, Ian E Krop, Patricia LoRusso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2017
Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot StudyRamesh K Ramanathan, Ronald L Korn, Natarajan Raghunand, et al.
Toxicology and Applied Pharmacology|June 9, 2012
HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicityJoseph G Reynolds, Elena Geretti, Bart S Hendriks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2017
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast CancerHelen Lee, Anthony F Shields, Barry A Siegel, et al.
Journal of Critical Care|December 22, 2020
Clinically relevant potential drug-drug interactions in intensive care patients: A large retrospective observational multicenter studyTinka Bakker, Ameen Abu-Hanna, Dave A Dongelmans, et al.
Pageof 9